Blood cancer startup targets treatment personalization

Matt De Silva was working at Peter Thiel’s hedge fund, Clarium Capital, when he learned his father had three rare brain tumors. That discovery led De Silva to a deep dive into personalized cancer drug recommendations — and ultimately toward founding Notable Labs. The Foster City-based company pairs artificial intelligence software with flow cytometry lab […]

Stanford, Notable Labs and Tempus collaborate on personalized medicine research for blood cancer

The feasibility study was meant to see whether personalized cancer genetic sequencing and drug sensitivity recommendations could be done in a “clinically reasonable amount of time.” The future of personalized cancer treatments will be enabled by technology to understand the genetic variants of a person’s disease, as well as tools to determine the best treatment […]

Notable Labs brings on 2 development executives ahead of its first blood cancer trials

has brought on two biopharma executives to take charge of its clinical operations and drug development work. Incyte’s Hiroomi Tada joined as chief medical officer, while Aquinox’s Lloyd Mackenzie will serve as chief development officer. Tada was most recently vice president of targeted therapies and translational sciences at Incyte, where he helped guide the company’s […]

,

Notable Founder Pete Quinzio Reflects on his 2018 Man of the Year Experience

Pete Quinzio (Notable Labs) & Catherine Finn (Salesforce) 2018 Bay Area Man and Woman of the Year At Notable we are immensely proud of Founder, Pete Quinzio who recently raised over $200,000 in 10 weeks for leukemia and lymphoma research. As nominations open for 2019 we sat down with Pete to ask him about his […]

Oncology Startup Notable Labs Donates its First Pediatric Therapy to Repurposing Non­Profit

Notable Labs is donating commercial rights to price, manufacture and distribute pediatric leukemia drug to non­profit Cures Within Reach FOSTER CITY, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) ­­ Notable Labs, a startup that accelerates drug development by matching drugs with patients who are most likely to respond, announced today that it has launched its first […]

Notable Labs Collaborator at ASH Shows Company’s Platform Predicts Ex Vivo Drug Response in Myeloid Neoplasms

SAN DIEGO and FOSTER CITY, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) — Notable Labs, Inc., a mission-driven company aiming to transform the way cancer is treated, announced today that the Company and its collaborators will present results of their research at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December […]

The Leukemia & Lymphoma Society Presents Man & Woman of the Year

Man & Woman of the Year is philanthropic competition to support blood cancer research among a group of motivated and dedicated individuals in communities across the United States. Candidates form powerful fundraising teams and compete in honor of two local children who are blood cancer survivors. The man and woman who have raised the most […]

Tech investors take a Warren Buffett approach to raising money for blood cancer research

Venture capitalist David Lee was diagnosed with Hodgkin’s lymphoma 24 years ago when he was a graduate Student at Stanford. Rhett Krawitt’s acute lymphoblastic leukemia was discovered eight years ago when he was just a toddler. Both are now cancer-free. Lee has a thriving investment career in Los Angeles and Krawitt is a Bay Area […]

In the next few weeks, you can spend time with any one of these VCs and it will all go to charity

Five years ago, we told you about a venture capital auction wherein dozens of VCs donated their time toward a greater good — helping fund research at the Leukemia & Lymphoma Society, one of the world’s largest voluntary health organizations dedicated to funding research and access to treatments for blood cancer patients. The auction was […]

Here’s the Problem with Today’s Human Clinical Trials

LAGUNA NIGUEL, Calif.—The cost to develop and gain FDA approval for a new drug today is more than $2.5 billion, according to the Tufts Center for the Study of Drug Development. Driving much of that cost are human clinical trials. They’re necessary, from a regulatory standpoint as well as an intellectual one. And of course […]